CytomX Therapeutics Inc - Asset Resilience Ratio

Latest as of June 2026: 82.12%

CytomX Therapeutics Inc (CTMX) has an Asset Resilience Ratio of 82.12% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See CTMX working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

$313.06 Million

Cash + Short-term Investments

Total Assets

$381.23 Million

All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2013–2025)

This chart shows how CytomX Therapeutics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of CytomX Therapeutics Inc.

Liquid Assets Composition Over Time

This chart breaks down CytomX Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore CytomX Therapeutics Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$313.06 Million	82.12%
Total Liquid Assets	$313.06 Million	82.12%

Asset Resilience Insights

Very High Liquidity: CytomX Therapeutics Inc maintains exceptional liquid asset reserves at 82.12% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

CytomX Therapeutics Inc Industry Peers by Asset Resilience Ratio

Compare CytomX Therapeutics Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
ALK-Abelló A/S CO:ALK-B	Biotechnology	0.98%
Mirum Pharmaceuticals Inc NASDAQ:MIRM	Biotechnology	6.89%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
BB Biotech AG SW:BION	Biotechnology	92.97%
Soleno Therapeutics Inc NASDAQ:SLNO	Biotechnology	20.15%
Nanobiotix NASDAQ:NBTX	Biotechnology	4.71%
Wuhan Keqian Biology Co Ltd SHG:688526	Biotechnology	19.42%
Beijing Konruns Pharmaceutical Co Ltd SHG:603590	Biotechnology	10.55%

Annual Asset Resilience Ratio for CytomX Therapeutics Inc (2013–2025)

The table below shows the annual Asset Resilience Ratio data for CytomX Therapeutics Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	82.07%	$124.39 Million	$151.57 Million	+30.15pp
2024-12-31	51.91%	$62.57 Million	$120.53 Million	-26.06pp
2023-12-31	77.97%	$157.34 Million	$201.79 Million	+39.76pp
2022-12-31	38.21%	$99.70 Million	$260.89 Million	+8.84pp
2021-12-31	29.37%	$99.70 Million	$339.41 Million	-5.27pp
2020-12-31	34.65%	$124.26 Million	$358.66 Million	+3.08pp
2019-12-31	31.56%	$107.72 Million	$341.28 Million	-9.69pp
2018-12-31	41.25%	$188.55 Million	$457.11 Million	-8.18pp
2017-12-31	49.43%	$196.56 Million	$397.64 Million	+10.62pp
2016-12-31	38.82%	$77.29 Million	$199.13 Million	-25.52pp
2015-12-31	64.34%	$126.89 Million	$197.22 Million	+64.20pp
2014-12-31	0.14%	$100.00K	$73.06 Million	-0.57pp
2013-12-31	0.71%	$100.00K	$14.18 Million	--

pp = percentage points

About CytomX Therapeutics Inc

NASDAQ:CTMX USA Biotechnology

Market Cap

$614.48 Million

Market Cap Rank

#11256 Global

#2921 in USA

Share Price

$2.82

Change (1 day)

+1.99%

52-Week Range

$1.98 - $6.75

All Time High

$34.22